Why Only 1 in 5 HealthTech Startups Succeeds in Raising External Capital

Only 19% of healthtech startups successfully raise external capital, often failing due to poor preparation rather than a lack of funds. To bridge this gap, R2GConnect’s free “Get Investor-Ready” track offers expert-led sessions on regulatory strategy, market intelligence, and pitch refinement to help founders secure funding.

Over the past few years, and following the post-COVID investment dip, several market analysts have reported a stabilization of investment activity in the healthtech sector. Global healthtech investment headlines have pointed to a recovery, with the hype around AI-enabled solutions contributing to larger and more frequent funding rounds over the past year.

However, this positive narrative masks a different reality for most companies. The vast majority of healthtech firms continue to struggle to secure funding. Within the R2G Connect healthtech community, 73% of companies are currently seeking external financing. Of these, fewer than 30% have entered investor discussions, and only 12–19% have successfully raised capital[1].

Capital is flowing, but primarily toward startups that already appear de-risked, defensible, and ready for institutional investment. All others are competing in a silent, overcrowded middle, where investor attention has largely collapsed.

The reasons many companies fail to raise capital are often structural such as insufficient technology readiness, weak business models, or limited founding team experience in building and scaling companies.

Capital is increasingly concentrated in late-stage and category-leading companies, legacy COVID-era valuations make many startups appear stalled, and strong investor focus on AI has crowded out non-AI solutions unless they are deeply embedded in clinical workflows or regulated pathways.

At the same time, investor expectations have tightened, with clinical evidence, regulatory readiness, reimbursement clarity, and proven economic impact now considered minimum requirements rather than differentiators, while long sales cycles and regulatory uncertainty raise perceived risk. Combined with weak unit economics, rising cost structures, limited exit visibility, and business models that lack platform depth or scalability, these factors have significantly increased the funding threshold across team experience, technology readiness, and capital efficiency.

In addition, more practical barriers play a significant role, including limited access to investors, difficulties in closing term sheets, and the absence of a sustained pipeline of investor capital.

1. Undifferentiated investor outreach: Many startups approach investors without a clear targeting strategy, contacting funds whose investment focus, stage, or geography do not match the company’s profile. This significantly reduces response rates and weakens credibility.
2. Mass distribution of pitch decks: Sending the same pitch deck to a broad, unfiltered investor list signals a lack of preparation. Investors can quickly identify generic outreach, which often results in immediate disengagement.
3. Weak or inconsistent investor story pitch materials: Pitch decks frequently lack a clear investment narrative, robust market sizing, or defensible differentiation. Inconsistent metrics, unclear traction, or overly technical storytelling further undermine investor confidence.
4. Lack of ongoing investor communication and reporting: Many companies fail to maintain regular updates with potential investors after initial contact. Without transparent progress reporting, milestones, and KPIs, trust erodes and momentum in the fundraising process is lost.
5. Insufficient fundraising readiness and process knowledge: Data rooms are often incomplete or poorly structured, and founders may lack a clear understanding of funding instruments, valuation mechanics, and the overall investment process. This leads to delays, friction during due diligence, and missed funding opportunities.

The Bottom Line Founders Miss

Most healthtech startups don’t fail at fundraising because they lack a good solutions or business case. They fail because they enter the capital market unprepared.

That gap between ambition and investor readiness is where most startups quietly fall out of the funnel.

Bridging the Gap: The Get Investor-Ready Track

At R2GConnect, we see this pattern repeatedly across regions, categories, and stages.

That’s why we launched the Get Investor-Ready Track: a focused, expert-led program designed to help healthtech startups to prepare their funding journey better.

The track brings together regulatory experts, market intelligence specialists, investor targeting partners, and pitch reviewers to help startups move from interesting to investable.

If the capital bar has risen, this is about helping you clear it deliberately, not hopefully.

Applications close February 15, 2026. Apply to the Get Investor-Ready Track Here.

[1] R2GConnect research